Tracy Brett, Shrestha Roshan, Stein Lance, Bhasin Devina, Pollinger Harrison, Rubin Raymond A
Department of Surgery, Memorial University Medical Center, Savannah, GA, USA.
Department of Transplantation, Piedmont Transplant Institute, Atlanta, GA, USA.
Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12690. Epub 2017 Apr 17.
Although chronic hepatitis C is still the leading indication for liver transplantation (LT) in the United States and Europe, acute liver failure caused by hepatitis C is distinctly uncommon and transplantation for fulminant hepatitis C virus (HCV) has not been documented in the United States. We present a case report of fulminant hepatic failure caused by genotype 2a/c HCV not only treated with LT but also complicated by severe, rapid recurrence of HCV within 6 days of transplantation. The risk factor for the initial infection was likely sexual, and there were no explanations for acute hepatitis post-transplant other than recurrent hepatitis C. Treatment with all-oral direct antiviral agents was swiftly initiated during the index hospitalization, leading to resolution of the acute hepatitis and resulting in sustained virologic response. It can only be speculated whether this was an infection with the JFH-1 strain or another similarly virulent genotype 2a/c HCV infection.
尽管在美国和欧洲,慢性丙型肝炎仍是肝移植(LT)的主要指征,但丙型肝炎引起的急性肝衰竭明显不常见,美国尚未有暴发性丙型肝炎病毒(HCV)移植的记录。我们报告一例由2a/c型HCV引起的暴发性肝衰竭病例,该患者不仅接受了肝移植治疗,且在移植后6天内出现严重、快速的HCV复发。初始感染的危险因素可能是性传播,除复发性丙型肝炎外,移植后急性肝炎没有其他解释。在首次住院期间迅速开始使用全口服直接抗病毒药物治疗,导致急性肝炎消退并实现持续病毒学应答。只能推测这是JFH-1毒株感染还是另一种同样具有高毒性的2a/c型HCV感染。